植入式直肠间隔球囊用于炎症性肠病前列腺癌放疗的安全性与有效性
该前瞻性单中心小样本系列纳入8例合并炎症性肠病(IBD)的前列腺癌患者,其中4例克罗恩病、4例溃疡性结肠炎,1例为活动期。所有患者接受根治性高剂量放疗并联合可降解前列腺-直肠间隔球囊植入;中位随访13个月,仅观察到1例急性2级胃肠道毒性,无晚期3级及以上胃肠道毒性,无急性或晚期2级及以上泌尿生殖毒性。提示该联合方案在选择性IBD患者中可能安全,但需进一步验证。
要点
- 8例合并IBD的前列腺癌患者接受球囊植入联合根治性放疗,耐受性良好。
- 仅1例出现急性2级胃肠道毒性(腹泻加重),6周后完全缓解。
- 未观察到晚期3级及以上胃肠道毒性或2级及以上泌尿生殖毒性。
核心结论
- 联合可降解前列腺-直肠间隔球囊的放疗在选择性合并IBD的前列腺癌患者中可能安全有效。
- 该方案仍需额外验证。
研究设计与样本
- 前瞻性单中心小样本系列,纳入8例合并IBD的全部风险组前列腺癌患者。
- 4例克罗恩病,4例溃疡性结肠炎;其中1例IBD处于活动期。
- 5例接受外照射放疗(70 Gy/28次),3例接受125I植入(145 Gy)。
- 毒性按CTCAE v4.03评分,急性副作用为放疗后3个月内,晚期副作用为3个月后。
主要发现
- 中位随访13个月(范围3-42个月)。
- 仅观察到1例急性2级胃肠道毒性:放疗期间腹泻较基线增加4-6次,治疗后6周完全缓解。
- 未报告晚期3级及以上胃肠道毒性。
- 未观察到急性或晚期2级及以上泌尿生殖毒性事件。
临床怎么用
- 对选择性合并(活动期)IBD的前列腺癌患者,可考虑放疗联合可降解直肠间隔球囊植入以降低直肠毒性风险。
- 治疗期间需按CTCAE v4.03密切监测急性和晚期胃肠道及泌尿生殖毒性。
局限性
- 样本量小(仅8例),单中心、前瞻性系列。
- 中位随访仅13个月,晚期毒性评估时间有限。
- 需额外验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer radiotherapy (RT) in patients with (active) inflammatory bowel disease (IBD) remains controversial. We hypothesized that RT in combination with a biodegradable prostate-rectum spacer balloon implantation, might be a safe treatment approach with acceptable toxicities for these high risk for rectal toxicity patients. MATERIALS AND METHODS: We report on a small prospective mono-centric series of 8 patients with all-risk prostate cancer with the comorbidity of an IBD. Four patients had Crohn's disease and 4 patients had ulcerative colitis. One out of four had an active status of IBD. All patients were intended to be treated with curative high-dose RT: 5 patients were treated with external beam RT (70 Gray (Gy) in 28 fractions), and 3 patients were treated with 125I-implant (145 Gy). Toxicities were scored according to the CTCAE v4.03: acute side effects occur up to 3 months after RT, and late side effects start after 3 months. RESULTS: Median follow-up was 13 months (range: 3-42 months). Only one acute grade 2 gastro-intestinal (GI) toxicity was observed: an increased diarrhea (4-6 above baseline) during RT, which resolved completely 6 weeks after treatment. No late grade 3 or more GI toxicity was reported, and no acute and late grade ≥2 genitourinary toxicity events were observed. CONCLUSION: Prostate cancer patients with IBD are a challenge to treat with RT. Our results suggest that RT in combination with a balloon implant in selective patients with (active) IBD may be promising, however additional validation is needed.
引用
- Vanneste BGL, Van Limbergen EJ, Marcelissen T, et al. Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? Clin Transl Radiat Oncol. 2021. PMID: 33604459. doi:10.1016/j.ctro.2021.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。